{"entity":{"id":"nct06908993","kind":"trial","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","aka":["COMET"],"tldr":"A phase 3 trial of tepotinib, pemetrexed, vinorelbine, docetaxel and other drugs in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, now recruiting.","summary":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated is a phase 3, randomised interventional study registered as NCT06908993 by Intergroupe Francophone de Cancerologie Thoracique, with a registry enrolment figure of 133 participants, started 2025-12-09 and due to reach its primary completion in 2028-03-15. Interventions recorded: Tepotinib; Pemetrexed (Alimta); Vinorelbine; Gemcitabine alone; Docetaxel; Paclitaxel; Pembrolizumab; Nivolumab; Atezolizumab. Conditions listed: Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: \"Histologically proven advanced NSCLC\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06908993","url":"https://clinicaltrials.gov/study/NCT06908993"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["met-altered-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","kinase-inhibitors"],"targets":[],"drugs":["tepotinib","pemetrexed","vinorelbine","docetaxel","paclitaxel","pembrolizumab","nivolumab","atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06908993","phase":"3","setting":"A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","enrolled":133,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06908993/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/"},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}